Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (Nasdaq: FULC) granted non‑statutory stock options to one new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The company awarded 34,000 options at an exercise price of $7.81 per share (closing price on March 2, 2026).
The options carry a 10‑year term and vest over four years: 25% on the first anniversary of employment, then 6.25% quarterly over the following 12 quarters, subject to continued service. The award was made pursuant to the company’s 2022 Inducement Stock Incentive Plan.
Fulcrum Therapeutics (Nasdaq: FULC) will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10, 2025 at 1:00 p.m. ET.
The presentation will be webcast and accessible via the company’s Events and Presentations investor web page, with a replay available for at least 30 days after the event.
Fulcrum Therapeutics (Nasdaq: FULC) reported positive 12-week Phase 1b PIONEER data for pociredir in sickle cell disease, with mean absolute fetal hemoglobin (HbF) rising 12.2% from 7.1% to 19.3% at Week 12 and improvements in hemolysis, anemia markers, and VOC trends.
The company ended 2025 with $352.3 million cash and plans a potential registration-enabling trial in H2 2026, expecting cash runway into 2029.
Fulcrum Therapeutics (Nasdaq: FULC) reported positive 12-week results from the 20 mg cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Mean absolute fetal hemoglobin (HbF) rose by 12.2% to 19.3%, F-cells increased from 31% to 63%, mean hemoglobin rose by 1.1 g/dL, and markers of hemolysis improved. Seven of 12 patients achieved HbF ≥20% and seven reported zero VOCs during treatment. Pociredir was generally well-tolerated with no treatment-related SAEs. Fulcrum plans a potential registration-enabling trial in H2 2026 and will discuss next-step design with regulators.
Fulcrum Therapeutics (Nasdaq: FULC) will present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on Tuesday, February 24, 2026 at 8:00 a.m. ET.
Management and Dr. Martin Steinberg will discuss the data via live webcast; registration is available on the company’s Events and Presentations page and a replay will be posted after the event.
Fulcrum Therapeutics (Nasdaq: FULC) granted non‑statutory inducement stock options to a new employee under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The grant was for 70,000 options at an exercise price of $10.72, the closing price on Feb 2, 2026. Options have a 10‑year term and vest over four years: 25% at the first anniversary of employment, then 6.25% quarterly for the following 12 quarters, subject to continued service.
Fulcrum Therapeutics (Nasdaq: FULC) granted inducement non‑statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan in reliance on Nasdaq Listing Rule 5635(c)(4).
The company granted a total of 30,400 options at an exercise price of $10.84 per share, equal to the closing price on the grant effective date, January 5, 2026. Each option has a 10‑year term and vests over four years: 25% on the first anniversary of employment, then 6.25% quarterly for the following twelve quarters, subject to continued service.
Fulcrum Therapeutics (Nasdaq: FULC) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 10:30 a.m. ET / 7:30 a.m. PT.
A live webcast will be accessible via Fulcrum's Events and Presentations page and a replay will be available on the company's website for at least 30 days following the presentation.
Fulcrum Therapeutics (Nasdaq: FULC) priced an upsized underwritten public offering to raise approximately $175.0 million in gross proceeds. The offering consists of 11,851,853 shares of common stock at $13.50 per share and, in lieu of common stock to certain investors, 1,111,193 pre-funded warrants at $13.499 each (exercise price $0.001). Fulcrum granted underwriters a 30-day option to buy up to an additional 1,944,456 shares on the same terms. Net proceeds are intended primarily for general corporate purposes, including working capital, R&D and clinical trials, regulatory submissions, commercialization, and potential acquisitions.
The offering is expected to close on or about December 11, 2025 and is being made under an effective shelf registration previously declared effective by the SEC.
Fulcrum Therapeutics (Nasdaq: FULC) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. All shares are to be sold by the company under an effective shelf registration previously filed with the SEC. Book-running managers include J.P. Morgan, Leerink Partners, and Cantor, with Oppenheimer and Truist also participating.
Fulcrum intends to use net proceeds for general corporate purposes, including R&D, clinical trials, regulatory submissions, commercialization, capital expenditures, and potential acquisitions. The offering is subject to market and other conditions; final terms will appear in a prospectus supplement filed with the SEC.